Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice

International Journal of Cancer

Volumn 67, Issue 1, 1996, Pages 113-123

  Reiter, Yoram ^a   Wright, Andrew F ^b   Tonge, David W ^b   Ann, Ira Past ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DISULFIDE; HYBRID PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 55.1; PSEUDOMONAS EXOTOXIN; RECOMBINANT IMMUNOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PSEUDOMONAS; SEQUENCE ANALYSIS; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL TOXINS; BASE SEQUENCE; COLONIC NEOPLASMS; EXOTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; VIRULENCE FACTORS;

EID: 0030054910     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960703)67:1<113::AID-IJC19>3.0.CO;2-F     Document Type: Article

References (30)

1. a epitope on distinct core protein. J. biol. Chem., 266, 21537-21547 (1991).
2. BATRA, J.K., KASPRZYK, P.G., BIRD, R.E., PASTAN, I. and KING, R.C., Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. nat. Acad. Sci. (Wash.), 89, 5867-5871 (1992).
3. BENHAR, I. and PASTAN, I., Characterization of Bl(Fv)-PE38 and Bl(dsFv)-PE38: single-chain and disulfide-stabilized Fv-immunotoxins with increased activity which cause complete remissions of established human carcinoma xenografts in nude mice. Clin. Cancer Res., 1, 1023-1029 (1995).
4. BIRD, R.E., HARDMAN, K.D., JACOBSON, J.W., JOHNSON, S., KAUFMAN, B.M., LEE, S.-M., LEE, T., POPE, S.H., RIORDAN, G.S. and WITHLOW, M., Single-chain antigen binding proteins. Science, 242, 423-426 (1988).
5. BRINKMANN, U., PAI, L.H., FITZGERALD, D.J., WILLINGHAM, M. and PASTAN, I., B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. nat. Acad. Sci. (Wash.), 88, 8616-8620 (1991).
6. BRINKMANN, U., REITER, Y., JUNG, S.-H., LEE, B. and PASTAN, I., A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc. nat. Acad. Sci. (Wash.), 90, 7538-7542 (1993).
7. BUCHNER, J., PASTAN, I. and BRINKMANN, U., A method to increase the yield of properly folded recombinant fusion proteins, e.g., single-chain immunotoxms, from renaturations of bacterial inclusion bodies. Anal. Biochem., 205, 263-270 (1992).
8. CALRETE, J.A., NEWELL, D.R., WRIGHT, A.F, and ROSE, M.S., In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A chain immunotoxin for the treatment of colorectal cancer. Cancer Res., 54, 4684-4690 (1994).
9. CHAUDHARY, V.K., JINNO, Y., FITZGERALD, D.J. and PASTAN, I., Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. nat. Acad. Sci. (Wash.), 87, 308-312 (1990).
10. CHAUDHARY, V.K., QUEEN, C. JUNGHANS, R.P., WALDMANN, T.A., FITZGERALD, D.J. and PASTAN, I., A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (Lond.), 339, 394-397 (1989).
11. DEBINSKI, W., KARLSSON, B., LINDHOLM, L., SIEGALL, C.B., WILLINGHAM, M.C., FITZGERALD, D.J. and PASTAN, I., Monoclonal antibody C242-Pseudomonas exotoxin A: a specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J. clin. Invest., 90, 405-411 (1992).
12. DEBINSKI, W. and PASTAN, I., Recombinant F(ab)' C242-Pseudomonas exotoxin but not the whole antibody based immunotoxin, causes regression of a human colorectal tumor xenograft. Clin. Cancer Res., 1, 1015-1022 (1995).
13. GENDLER, S., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., ROTHBARD, J. and BURCHELL, J., A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. biol. Chem., 263, 12820-12823 (1988).
14. HUSTON, J.S., LEVINSON, D., MUDGETT-HUNTER, M., TAI, M.S., NOVOTNY, J., MARGOLIES, M.N., RIDGE, R.J., BRUCCOLERI, E.H., CREA, R. and OPPERMANN, H., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin singlechain Fv analogue produced in Escherichia coll Proc. nat. Acad. Sci. (Wash.), 85, 5879-5883 (1988).
15. HWANG, J., FITZGERALD, D.J., ADHYA, S. and PASTAN, I., Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell, 48, 129-136 (1987).
16. KLUG, T.L., LEDONNE, N.C., GREBER, T.F. and ZURAWSKI JR., V.R., Purification and composition of a novel gastrointestinal tumorassociated glycoprotein expressing sialyated lacto-N-fucopentaose II (CA 19-9). Cancer Res., 48, 1505-1511 (1988).
17. KONDO, T., FITZGERALD, D.J., CHAUDHARY, V.K., ADHYA, S. and PASTAN, I., Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J. biol. Chem., 263, 9470-9475 (1988).
18. LAN, M.S., BAST JR., R.C., COLNAGHI, M.I., KNAPP, R.C., COLCHER, D., SCHLOM, J. and METZGAR, R.S., Co-expression of human cancerassociated epitopes on mucin molecules. Int. J. Cancer, 39, 68-72 (1987a).
19. LAN, M.S., KHORRAMI, A., KAUFMAN, B. and METZGAR, R.S., Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The DU-PAN-2 antigen. J. biol. Chem., 262, 12863-12870 (1987b).
20. LIGTENBERG, M.J.L., Vos, H.L., GENNISSEN, A.M.C. and HILKENS, J., Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. biol. Chem., 265, 5573-5578 (1990).
21. NEUTRA, M.R. and FORSTER, J.F., Structure and function as the large intestine. In: L.R. Johnson (ed.), Physiology of the gastrointestinal tract (2nd ed.), pp. 975-1009, Raven Press, New York (1989).
22. PASTAN, I. and FITZGERALD, D., Recombinant toxins for cancer treatment. Science, 254, 1173-1177 (1991).
23. REITER, Y., BRINKMANN, U., JUNG, S.-H., LEE, B., KING, C.R. and PASTAN, I., Improved binding and anlitumor activity of a recombinant anti-erbB2 immunotoxins by disulfide stabilization of the Fv fragment. J. biol. Chem., 269, 18327-18331 (1994a).
24. REITER, Y., BRINKMANN, U., KREITMAN, R., JUNG, S.-H., LEE, B. and PASTAN, I., Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33, 5451-5459 (1994b).
25. REITER, Y., BRINKMANN, U., WEBBER, K.O., JUNG, S.-H., LEE, B. and PASTAN, I., Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Engin., 7, 697-704 (1994c).
26. REITER, Y., PAI, L.H., BRINKMANN, U., WANG, Q.-C. and PASTAN, I., Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res., 54, 2714-2718 (1994d).
27. SEETHARAM, S., CHAUDHARY, V.K., FITZGERALD, D. and PASTAN, I., Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. biol. Chem., 266, 17376-1738 (1991).
28. SHEER, D.G., SCHLOM, J. and COOPER, H.L., Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res., 48, 6811-6818 (1988).
29. VITETTA, E. and THORPE, P.E., Immunotoxins containing ricin or its A chain. Semin. Cell. Biol., 2, 43-58 (1991).
30. YOKOTA, T., MILENIC, D.E., WITHLOW, M. and SCHLOM, J., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52, 3402-3408 (1992).